DrugPatentWatch Database Preview
Drugs in Development Information for HKI-357
» See Plans and Pricing
What is the drug development status for HKI-357?
HKI-357 is an investigational drug.
There have been 22 clinical trials for HKI-357.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2009.
The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are Puma Biotechnology, Inc., Dana-Farber Cancer Institute, and Translational Breast Cancer Research Consortium.
Summary for HKI-357
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 9 |
| WIPO Patent Applications | 106 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2009-07-01) |
| Vendors | 19 |
Recent Clinical Trials for HKI-357
| Title | Sponsor | Phase |
|---|---|---|
| HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | Translational Breast Cancer Research Consortium | Phase 2 |
| HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | Dana-Farber Cancer Institute | Phase 2 |
| Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | Puma Biotechnology, Inc. | Phase 2 |
Clinical Trial Summary for HKI-357
Top disease conditions for HKI-357
Top clinical trial sponsors for HKI-357
US Patents for HKI-357
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
